Cell Kinetics Ltd. (CKNTF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cell Kinetics Ltd. (CKNTF) with AI Score 46/100 (Weak). Cell Kinetics Ltd. focuses on refining and commercializing CellScan technology. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 18, 2026Cell Kinetics Ltd. (CKNTF) Healthcare & Pipeline Overview
Cell Kinetics Ltd., a subsidiary of Medis Technologies, specializes in cell carrier technology, specifically the CKChip platform, enabling simultaneous examination of live cells through imaging. Operating in the medical devices sector, the company focuses on refining and commercializing CellScan technology for advanced cell analysis applications.
Investment Thesis
Cell Kinetics Ltd. presents a focused investment opportunity within the medical devices sector, centered on its CKChip platform for cell analysis. The company's technology enables detailed examination of live cells, potentially driving adoption in research and diagnostic applications. A key value driver is the continued refinement and commercialization of CellScan technology, targeting a market need for efficient cell analysis tools. Growth catalysts include expanding the applications of CKChip technology and securing partnerships within the healthcare and research sectors. However, potential risks include the company's OTC listing, limited financial information, and competition from established players in the cytometry market. With a market capitalization of $0.00B and a beta of -10.63, the company's financial profile requires careful consideration.
Based on FMP financials and quantitative analysis
Key Highlights
- Cell Kinetics Ltd. specializes in cell carrier technology known as CKChip.
- The CKChip platform enables simultaneous examination of various individual live cells.
- The company's technology uses simple imaging methods such as fluorescence microscopy.
- Cell Kinetics Ltd. was founded in 1992 and is headquartered in Lod, Israel.
- The company is a subsidiary of Medis Technologies Ltd.
Competitors & Peers
Strengths
- Proprietary CKChip technology for cell analysis.
- Focus on static cytometry.
- Potential for cost-effective live cell examination.
Weaknesses
- OTC listing and limited financial information.
- Small company size and limited resources.
- Dependence on Medis Technologies Ltd.
Catalysts
- Upcoming: Potential partnerships with diagnostic companies to integrate CKChip technology into diagnostic assays.
- Ongoing: Continued refinement and commercialization of CellScan technology.
- Ongoing: Efforts to expand the applications of CKChip technology.
Risks
- Potential: Competition from established players in the cytometry market.
- Potential: Regulatory hurdles for new diagnostic applications.
- Ongoing: OTC listing and limited financial information.
- Ongoing: Small company size and limited resources.
Growth Opportunities
- Expansion into Research Institutions: Cell Kinetics can target research institutions and universities to adopt the CKChip platform for advanced cell analysis. The market for research tools in cell biology is substantial, with institutions continuously seeking innovative technologies. By demonstrating the efficiency and cost-effectiveness of CKChip, Cell Kinetics can penetrate this market, potentially securing long-term contracts and collaborations. This expansion could be realized within the next 1-2 years, driving revenue growth and establishing the company as a key player in research applications.
- Partnerships with Diagnostic Companies: Collaborating with diagnostic companies to integrate CKChip technology into diagnostic assays represents a significant growth opportunity. The demand for accurate and rapid diagnostic tools is increasing, and CKChip's ability to analyze live cells can enhance the precision of diagnostic tests. Forming strategic partnerships with companies specializing in cancer diagnostics or infectious disease testing can accelerate market penetration and generate revenue through licensing agreements and joint product development. These partnerships could materialize within the next 2-3 years, contingent on successful validation studies and regulatory approvals.
- Development of New Applications for CKChip: Cell Kinetics can invest in research and development to explore new applications for the CKChip platform beyond its current capabilities. This includes adapting the technology for use in drug discovery, personalized medicine, and regenerative medicine. By expanding the range of applications, Cell Kinetics can attract a broader customer base and diversify its revenue streams. The development of new applications may take 3-5 years, requiring sustained investment in R&D and collaboration with experts in relevant fields.
- Geographic Expansion into New Markets: Cell Kinetics can expand its geographic presence by targeting new markets in Europe and Asia. These regions have a growing demand for advanced cell analysis technologies, driven by increasing healthcare spending and research activities. Establishing distribution networks and partnerships in these markets can facilitate market entry and generate revenue growth. Geographic expansion can be pursued within the next 2-3 years, contingent on securing regulatory approvals and establishing local partnerships.
- Securing Government Grants and Funding: Cell Kinetics can actively pursue government grants and funding opportunities to support its research and development activities. Government agencies and research foundations often provide funding for innovative technologies in healthcare and biotechnology. Securing these grants can provide Cell Kinetics with additional resources to accelerate the development and commercialization of its CKChip platform. The timeline for securing grants varies depending on the specific funding programs, but ongoing efforts to identify and apply for relevant grants can yield positive results within the next 1-2 years.
Opportunities
- Expansion into research institutions and diagnostic companies.
- Development of new applications for CKChip technology.
- Geographic expansion into new markets.
Threats
- Competition from established players in the cytometry market.
- Regulatory hurdles for new diagnostic applications.
- Limited access to capital for growth and expansion.
Competitive Advantages
- Proprietary CKChip technology.
- Specialized focus on static cytometry.
- Potential for cost-effective cell analysis.
About CKNTF
Founded in 1992 and headquartered in Lod, Israel, Cell Kinetics Ltd. is dedicated to the advancement of cell analysis technologies. The company's core focus is the refinement and commercialization of CellScan and related technologies, with a particular emphasis on the CKChip platform. This platform employs static cytometry, allowing for the simultaneous examination of various individual live cells through simple imaging methods, such as fluorescence microscopy. The CKChip technology facilitates detailed cellular analysis, potentially impacting research and diagnostic applications. As a subsidiary of Medis Technologies Ltd., Cell Kinetics benefits from the resources and infrastructure of its parent company. The company's operations are centered around developing and marketing this cell carrier technology, aiming to provide researchers and clinicians with tools for advanced cell analysis. Cell Kinetics' technology is designed to offer a cost-effective and efficient method for examining live cells, potentially improving the speed and accuracy of cellular research and diagnostics. The company's strategic focus on static cytometry positions it within a niche market of cell analysis, where it aims to provide innovative solutions for live cell examination.
What They Do
- Refines and commercializes CellScan technology.
- Develops and commercializes CKChip, a cell carrier technology.
- Offers a platform for static cytometry.
- Enables simultaneous examination of various individual live cells.
- Uses simple imaging methods, such as fluorescence microscopy.
- Provides tools for advanced cell analysis.
Business Model
- Develops and sells cell carrier technology (CKChip).
- Commercializes CellScan technology.
- Generates revenue through sales of its technology to research institutions and diagnostic companies.
Industry Context
Cell Kinetics Ltd. operates within the medical devices industry, specifically focusing on cell analysis technologies. The market for cell analysis is driven by advancements in research and diagnostics, with increasing demand for tools that enable detailed cellular examination. The competitive landscape includes companies offering cytometry solutions, such as Maravai LifeSciences Holdings, Inc. (MRVT), and genetic testing services like Invitae Corporation (NVTAQ). Cell Kinetics' CKChip platform aims to provide a cost-effective and efficient method for live cell examination, positioning it within a niche segment of the broader cell analysis market.
Key Customers
- Research institutions
- Diagnostic companies
- Healthcare providers
Financials
Chart & Info
Cell Kinetics Ltd. (CKNTF) stock price: Price data unavailable
Latest News
No recent news available for CKNTF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CKNTF.
Price Targets
Wall Street price target analysis for CKNTF.
MoonshotScore
What does this score mean?
The MoonshotScore rates CKNTF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Stephen N. Crea
CEO
Stephen N. Crea serves as the CEO of Cell Kinetics Ltd., managing a team of 10 employees. His background includes experience in the healthcare and biotechnology sectors. While specific details on his educational background and previous roles are not available, his leadership is focused on guiding Cell Kinetics in the refinement and commercialization of its CellScan and CKChip technologies.
Track Record: Under Stephen N. Crea's leadership, Cell Kinetics Ltd. continues to focus on the development and commercialization of its cell carrier technology. Key milestones include ongoing efforts to expand the applications of CKChip and secure partnerships within the healthcare and research sectors. His strategic decisions are centered on driving adoption of the company's technology and enhancing its market presence.
CKNTF OTC Market Information
The OTC Other tier represents the lowest tier of over-the-counter (OTC) markets, indicating that Cell Kinetics Ltd. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited or no financial reporting, making it difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, resulting in higher risks for investors due to the lack of transparency and oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and illiquidity.
- Potential for price manipulation and fraud.
- Lack of regulatory oversight and investor protection.
- Higher risk of delisting or going out of business.
- Verify the company's legal status and registration.
- Attempt to obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Understand the company's business model and competitive landscape.
- Evaluate the company's technology and intellectual property.
- Consult with a financial advisor or legal expert.
- Be prepared to lose your entire investment.
- Company has been in operation since 1992.
- Focus on refining and commercializing CellScan technology.
- Subsidiary of Medis Technologies Ltd.
CKNTF Healthcare Stock FAQ
What does Cell Kinetics Ltd. do?
Cell Kinetics Ltd. specializes in the development and commercialization of cell analysis technologies, primarily focusing on its CKChip platform. This platform utilizes static cytometry to enable the simultaneous examination of individual live cells through imaging methods like fluorescence microscopy. The company aims to provide researchers and clinicians with cost-effective and efficient tools for advanced cell analysis, potentially improving the speed and accuracy of cellular research and diagnostics. As a subsidiary of Medis Technologies Ltd., Cell Kinetics benefits from the resources and infrastructure of its parent company.
What are the key growth opportunities for CKNTF in healthcare?
Cell Kinetics Ltd. has several growth opportunities within the healthcare sector. These include expanding into research institutions by offering the CKChip platform for advanced cell analysis, forming partnerships with diagnostic companies to integrate CKChip technology into diagnostic assays, developing new applications for CKChip in areas like drug discovery and personalized medicine, and expanding geographically into new markets in Europe and Asia. Securing government grants and funding can also provide additional resources for research and development.
How does Cell Kinetics Ltd. navigate regulatory approval processes?
As a company developing cell analysis technologies, Cell Kinetics Ltd. faces regulatory approval processes, particularly if its technology is integrated into diagnostic applications. The company needs to comply with regulations set by agencies like the FDA in the United States and the EMA in Europe. This involves conducting validation studies to demonstrate the safety and efficacy of its technology, preparing detailed documentation for regulatory submissions, and adhering to quality control standards throughout the development and manufacturing process. The timeline for regulatory approvals can vary depending on the specific application and the regulatory pathway pursued.
What are the key factors to evaluate for CKNTF?
Cell Kinetics Ltd. (CKNTF) currently holds an AI score of 46/100, indicating low score. Key strength: Proprietary CKChip technology for cell analysis.. Primary risk to monitor: Potential: Competition from established players in the cytometry market.. This is not financial advice.
How frequently does CKNTF data refresh on this page?
CKNTF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CKNTF's recent stock price performance?
Recent price movement in Cell Kinetics Ltd. (CKNTF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary CKChip technology for cell analysis.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CKNTF overvalued or undervalued right now?
Determining whether Cell Kinetics Ltd. (CKNTF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CKNTF?
Before investing in Cell Kinetics Ltd. (CKNTF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial information available due to OTC listing.
- AI analysis pending for CKNTF.